In kidney transplant recipients, sotagliflozin (SGLT1/2 inhibitor) caused an initial eGFR dip—but changes were largely reversible after withdrawal.
🔹Well tolerated overall
🔹Adherence unaffected by eGFR reporting strategy
Promising safety signal for KTRs
tinyurl.com/mv9p49k3